Advertisement
JOGC

The Canadian HIV Pregnancy Planning Guidelines: What Pregnancy Care Providers Need to Know About HIV Transmission and Pre-Conception Considerations

Published:November 30, 2020DOI:https://doi.org/10.1016/j.jogc.2020.09.022

      Abstract

      Today, under ideal conditions with combination antiretroviral therapy (cART), HIV is a chronic illness with a normal life expectancy. As such, people with HIV are pursuing experiences that once escaped them, such as parenthood. One of the most important factors in reducing perinatal HIV transmission was, and still is, adequate planning. And pregnancy planning has a few additional implications for people affected by HIV, not unlike for people with other chronic illnesses. In 2018, the updated Canadian HIV Pregnancy Planning Guidelines (CHPPGs) were published with 36 recommendations. To help pregnancy care providers use the CHPPGs in pregnancy planning counselling for people living with HIV and their partners, this paper summarizes 5 key considerations in the modern era of HIV management.

      Résumé

      De nos jours, dans des conditions idéales et lorsqu'il fait l'objet d'un traitement antirétroviral combiné, le VIH est une maladie chronique avec laquelle les personnes atteintes peuvent avoir une espérance de vie normale. Par conséquent, ces personnes aspirent à des expériences qui autrefois leur étaient refusées, notamment la parentalité. Un des plus importants facteurs de réduction de la transmission périnatale du VIH était et demeure la planification adéquate. La planification de la grossesse comporte quelques implications supplémentaires pour les personnes atteintes du VIH; comme c'est le cas pour celles qui souffrent d'autres maladies chroniques. La directive mise à jour intitulée Lignes directrices canadiennes en matière de planification de la grossesse en présence du VIH a été publiée en 2018 et comporte 36 recommandations. Afin d'aider les fournisseurs de soins obstétricaux à intégrer ces lignes directrices dans leurs conseils de planification de la grossesse pour les personnes atteintes du VIH et leur partenaire, cet article résume 5 considérations principales de l’ère moderne de la prise en charge du VIH.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission
        Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States.
        U.S. Department of Health and Human Services, 2020: 383
        • Centers for Disease Control and Prevention
        Achievements in public health: reduction in perinatal transmission of HIV infection — United States, 1985—2005.
        Department of Health and Human Services, Atlanta2006 (Available at:) (Accessed on April 10, 2020)
        • UNAIDS
        UNAIDS statement on the forced and coerced sterilization of women living with HIV.
        UNAIDS, Geneva2020 (Available at:) (Accessed on November 8, 2020)
        • Mandelbrot L
        • Tubiana R
        • Le Chenadec J
        • et al.
        No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.
        Clin Infect Dis. 2015; 61: 1715-1725
        • Loutfy M
        • Kennedy VL
        • Poliquin V
        • et al.
        No. 354-Canadian HIV pregnancy planning guidelines.
        J Obstet Gynaecol Can. 2018; 40: 1-21
        • Cohen MS
        • Chen YQ
        • McCauley M
        • et al.
        Antiretroviral therapy for the prevention of HIV-1 transmission.
        N Engl J Med. 2016; 375: 830-839
        • Rodger AJ
        • Cambiano V
        • Bruun T
        • et al.
        Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.
        Lancet. 2019; 393: 2428-2438
        • Yudin MH
        • Shapiro HM
        • Loutfy MR
        Access to infertility services in Canada for HIV-positive individuals and couples: a cross-sectional study.
        Reprod Health. 2010; 7: 1-6
        • Lo CK
        • Kennedy VL
        • Yudin MH
        • et al.
        Access to fertility services in Canada for HIV-positive individuals and couples: a comparison between 2007 and 2014.
        AIDS Care. 2017; 29: 1433-1436
        • Bujan L
        • Sergerie M
        • Moinard N
        • et al.
        Decreased semen volume and spermatozoa motility in HIV-1-infected patients under antiretroviral treatment.
        J Androl. 2007; 28: 444-452
        • Marston M
        • Zaba B
        • Eaton JW
        The relationship between HIV and fertility in the era of antiretroviral therapy in sub-Saharan Africa: evidence from 49 demographic and health surveys.
        Trop Med Int Heal. 2017; 22: 1542-1550
        • Nanda K
        • Stuart GS
        • Robinson J
        • et al.
        Drug interactions between hormonal contraceptives and antiretrovirals.
        AIDS. 2017; 31: 917-952
        • Ahmed K
        • Baeten JM
        • Beksinska M
        • et al.
        HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
        Lancet. 2019; 394: 303-313